Inhibition by stabilization: targeting the Plasmodium falciparum aldolase–TRAP complex by Sondra Maureen Nemetski et al.
Nemetski et al. Malar J  (2015) 14:324 
DOI 10.1186/s12936-015-0834-9
RESEARCH
Inhibition by stabilization: targeting the 
Plasmodium falciparum aldolase–TRAP complex
Sondra Maureen Nemetski1,9†, Timothy J Cardozo1,2*†, Gundula Bosch3,8, Ryan Weltzer4,8, Kevin O’Malley4,8, 
Ijeoma Ejigiri5, Kota Arun Kumar6,10, Carlos A Buscaglia7, Victor Nussenzweig6, Photini Sinnis3,5,8, 
Jelena Levitskaya3,8 and Jürgen Bosch4,8* 
Abstract 
Background: Emerging resistance of the malaria parasite Plasmodium to current therapies underscores the criti-
cal importance of exploring novel strategies for disease eradication. Plasmodium species are obligate intracellular 
protozoan parasites. They rely on an unusual form of substrate-dependent motility for their migration on and across 
host-cell membranes and for host cell invasion. This peculiar motility mechanism is driven by the ‘glideosome’, an 
actin–myosin associated, macromolecular complex anchored to the inner membrane complex of the parasite. Myosin 
A, actin, aldolase, and thrombospondin-related anonymous protein (TRAP) constitute the molecular core of the 
glideosome in the sporozoite, the mosquito stage that brings the infection into mammals.
Methods: Virtual library screening of a large compound library against the PfAldolase–TRAP complex was used to 
identify candidate compounds that stabilize and prevent the disassembly of the glideosome. The mechanism of these 
compounds was confirmed by biochemical, biophysical and parasitological methods.
Results: A novel inhibitory effect on the parasite was achieved by stabilizing a protein–protein interaction within 
the glideosome components. Compound 24 disrupts the gliding and invasive capabilities of Plasmodium parasites in 
in vitro parasite assays. A high-resolution, ternary X-ray crystal structure of PfAldolase–TRAP in complex with com-
pound 24 confirms the mode of interaction and serves as a platform for future ligand optimization.
Conclusion: This proof-of-concept study presents a novel approach to anti-malarial drug discovery and design. By 
strengthening a protein–protein interaction within the parasite, an avenue towards inhibiting a previously “undrug-
gable” target is revealed and the motility motor responsible for successful invasion of host cells is rendered inactive. 
This study provides new insights into the malaria parasite cell invasion machinery and convincingly demonstrates that 
liver cell invasion is dramatically reduced by 95 % in the presence of the small molecule stabilizer compound 24.
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Virtual library screening, X-ray crystal structure, Malaria
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Background
Despite recent advances in treatment and prevention, 
malarial disease continues to afflict hundreds of mil-
lions of people every year, with growing resistance to 
current therapies [1–5]. Innovative treatments targeting 
hitherto under-exploited aspects of plasmodial biology 
are needed.
Plasmodium, as with other protozoan parasites 
belonging to the phylum Apicomplexa, progress 
through their life cycle by invading host cells. Glid-
ing and active host cell invasion are thus crucial for 
these organisms, and are facilitated through an actin/
myosin motor complex located beneath the para-
site’s plasma membrane [6–8]. Herewith, the bridging 
enzyme PfAldolase, which binds actin in addition to its 
role in glycolysis [9], plays a key role: it connects the 
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actin/myosin motor to trans-membrane adhesins of the 
thrombospondin-related anonymous protein (TRAP) 
family, which are expressed in a life-cycle stage specific 
manner [10]. Thus, during plasmodial liver, blood and 
transmission stages, PfAldolase binds the conserved 
C-termini of the plasmodial paralogs TRAP, MTRAP 
and CTRP, respectively [10–15] as well as other inter-
action partners such as the cytoplasmic tail of AMA-1 
[16].
During the gliding and invasion processes, TRAP 
molecules are translocated from the anterior to the 
posterior end of the parasite, where they are cleaved 
within their transmembrane domain by a rhomboid 
protease [17, 18]. The cleavage reaction leaves the 
extracellular TRAP domains bound to the host cell 
or substrate, while the cytoplasmic C-termini, also 
referred to as TRAP-tails, remain bound to PfAldolase, 
from which they are believed to dissociate and be recy-
cled for degradation over time [18, 19]. Un-liganded 
PfAldolase molecules are then available for binding 
other TRAP molecules, thus enabling continuous glid-
ing motion on the host cell surface, which constitutes 
a necessary prerequisite for subsequent invasion [20]. 
A schematic overview of the glideosome components 
that were identified via combinatorial pull-down 
experiments in Plasmodium parasites [10] is given in 
Fig. 1a.
The study presented here aims to inhibit parasite 
motility and infectivity by targeting the aldolase–TRAP 
interaction within the glideosome. As an enzyme of the 
glycolytic pathway, however, aldolase is well conserved 
throughout all kingdoms (204/365 identical residues 
between human and Plasmodium aldolase, see Addi-
tional file  1). Inhibitor design targeting the PfAldolase 
molecule and its binding partners must therefore meet 
the challenge of avoiding cross-reactivity with human 
aldolase enzymes. This study employs a novel approach 
to rational drug design to meet this challenge.
While traditional, targeted inhibitor-design 
approaches are usually geared towards finding small 
molecules that prevent protein–protein interac-
tions (PPI) critical to the pathogen [21], the hypoth-
esis explored here is counter-intuitive: strengthening, 
instead of hindering, the PfAldolase–TRAP interaction 
is hypothesized to inhibit motility and invasion. The 
rationale for this counterintuitive approach is that the 
hybrid molecular surface formed partly by PfAldolase 
and partly by TRAP in the bound state of the complex 
is unique to the parasite and could allow Plasmodium-
specific targeting with small molecules that would not 
Fig. 1 Schematic overview of the glideosome components and principle of enzyme inhibition and complex stabilization. a The gliding machinery 
is anchored between the parasite plasma membrane and the inner membrane complex (IMC). Aldolase mediates a bridging function between 
short actin filaments and TRAP. b Simplified model of a single aldolase sub-unit with TRAP and F16P binding sites. TRAP-binding promoters (green) 
occlude access to the catalytic site of aldolase.
Page 3 of 18Nemetski et al. Malar J  (2015) 14:324 
cross-react with the human orthologues (Fig. 1b). More 
importantly, a fast dissociation of bound TRAP-tails 
(after protease cleavage) is critical for Plasmodium’s 
ability to recycle PfAldolase molecules during glid-
ing motility and host cell invasion [17, 18]. Therefore, a 
small molecule designed to strengthen the PfAldolase–
TRAP interaction should render this crucial dissociation 
process slow and inefficient, thus leading to an imbal-
ance of this dynamic system and concomitant locomo-
tion defects and likely reduced cell invasion. Equally 
importantly, the ternary complex of PfAldolase–TRAP 
and a stabilizing agent would be expected to interfere 
with glycolytic activity as the active site is occluded. It 
is unknown if the liver stage parasite relies on glycolytic 
activity for energy generation as does the blood stage 
form of the parasite [22]. However, PfAldolase is con-
stitutively expressed in blood and gametocytes stages, 
suggesting it may be expressed, and is likely required, 
during liver stages as well (PlasmoDB PF3D7_1444800). 
A similar approach to stabilizing a PPI is described by 
Mecozzi et  al. where they identified small molecules 
by virtual screening that were capable of stabilizing the 
Vps35–Vps26 interaction [23].
This hypothesis was tested using biophysical and bio-
chemical assays as well as in  vitro culture experiments 
with Plasmodium falciparum and Plasmodium berghei 
parasites to demonstrate that small molecules identified 
by virtual library screening (VLS) show an effect on glid-
ing motility and hepatocyte invasion. A primary screen, 
which was comprised of VLS, PfAldolase catalytic activ-
ity, and thermal stability in the presence of small mole-
cules, identified several compounds active in two or more 
assays. These were then further validated in two parasite 
specific assays, one investigating the impact on gliding 
motility and the second testing if parasites treated with 
small molecules are hindered in invasion of liver cells. 
Finally, the ternary co-crystal structure of PfAldolase–
TRAP with compound 24 stabilizing the interaction was 
determined. The ternary complex is observed in all four 




The screening library of 315,102 chemicals was provided 
as a structure description file (SDF) from the Chem-
bridge Corporation (San Diego, CA, USA), as previously 
described. Unless otherwise noted, all compounds used 
in the in vitro and in vivo assays were obtained in pow-
dered form from the Chembridge Corporation, and ini-
tially dissolved in 100 % DMSO to obtain 100 mM stock 
solutions, which were stored at 4  °C or −20  °C. When-
ever possible, working dilutions in the relevant buffers 
were made within 24 h of the experiments in which they 
were used.
Computational methods
All computational work, including receptor modelling, 
VLS, docking, and hit-list post-processing was completed 
using tools in the ICM software suite produced by Mol-
soft, LLC (Version 3.7, La Jolla, CA, USA) with default 
parameters. VLS was performed as previously described 
[24]. The PocketFinder function of ICM was used to ren-
der solvent pockets suitable for small molecule ligand 
binding on the molecular surface of 3D structural protein 
models as previously described [25]. The crystal structure 
of the PfAldolase TRAP complex present in PDB ID 2pc4 
was used as the starting point for all of the modelling, 
VLS and docking described in this study.
Expression and purification of Plasmodium falciparum 
aldolase
Cloning, expression, and purification of P. falciparum 
aldolase in Escherichia coli was performed using either of 
two previously described methods [26]. Prior to cataly-
sis assays, the GST-tag was removed from the tagged 
protein using the Novagen Factor Xa Cleavage-Capture 
Kit according to manufacturer’s instructions (EMD Bio-
sciences, San Diego, CA, USA).
Synthetic peptides
Synthetic peptides derived from the cytoplasmic tails 
of P. falciparum and P. berghei TRAP were custom-
synthesized by Genemed Synthesis, Inc (TX, USA). 
These included PfTRAP25 (ETLGEEDKDLDEPEQ 
FRLPEENEWN), PfTRAP6 (EENEWN), PbTRAP25 
(VMADDEKGIVEDEGFKLPEDNDWN), and PbTRAP6 
(EDNDWN).
Thermal shift assay
The results reported here measured the effect of the VLS 
hits on a complex of recombinant P. falciparum aldolase 
and the PbTRAP6 peptide described above. The assays 
were conducted and analysed as per previously published 
protocols in triplicates [27, 28].
Aldolase catalysis assay
The protocol utilized here was based on that provided by 
Sigma-Aldrich® (St. Louis, MO, USA), and all of the rea-
gents (listed below) other than drugs, TRAP and aldolase 
were obtained from that company as well. Briefly, aldo-
lase was pre-incubated for 10  min, +/− TRAP peptide 
(PfTRAP25, described above), +/− compound or DMSO 
at room temperature. The other reagents (α-GDH/TPI, 
β-NADH, F16P in order) were then added, yielding a 
final reaction mixture containing 0.02  units/ml aldolase 
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 (1 unit = amount of aldolase required to convert 1 μM of 
F16P to DHAP and G3P per minute at pH 7.4 and 25 °C; 
for these studies, this usually amounted to ~50 nM aldo-
lase, based on an estimated purification yield of 10 units/
mg aldolase), 2  mM F16P, 0.13  mM β-NADH, 2  units/
ml α-GDH/TPI (1 unit  =  amount of αGDH required 
to convert 1.0 μM of DHAP to α-glycerophosphate per 
min at pH 7.4 and 25  °C), 100  nM TRAP (or DMSO), 
and 5–100 μM compound (or DMSO) in catalysis buffer 
(0.2  M glycine titrated to pH 7.3 with Trizma Base). A 
buffer with low ionic strength was used to avoid interfer-
ence with the electrostatic interactions between aldolase 
and TRAP. Reactions were carried out either in a final 
volume of 1 ml, in standard plastic cuvettes (assays with 
PfTRAP25), or in a 96-well format with 100 µl reaction 
volume (assays with PbTRAP6). NADH consumption 
was measured at 340  nm for 10  min at 25  °C, using a 
SpectraMax M2e Microplate Reader (Molecular Devices, 
Sunnyvale, CA, USA). As many of the compounds had 
measurable inherent absorbance at 340 nm, the baseline 
absorbance of each compound when dissolved in cataly-
sis buffer at the tested concentration was measured and 
subtracted from the values obtained during the kinetic 
run. Suramin, a known aldolase inhibitor, was used as a 
positive control for aldolase inhibition [29].
To test if compound 24 had an inhibitory effect on 
human aldolase, rabbit muscle aldolase was used, which 
is 99.3 % sequence identical to human aldolase. The assay 
was performed as described previously, however in the 
absence of TRAP-peptide to identify if the compound 
inhibited catalytic activity by itself.
X‑ray crystallography
Compounds were co-crystallized with the PbTRAP6 pep-
tide and purified P. falciparum aldolase as per previously 
published protocols [26]. Crystallization trials of PfAldo-
lase with TRAP in the presence of different concentra-
tions of the small molecules were set up at 20 °C. In most 
cases crystals of different sizes appeared within 1  week, 
many of the small molecules resulted in precipitated solu-
tions at higher concentrations. Multiple synchrotron data-
sets were collected from crystals grown in the presence of 
2 mM compounds 1, 2, 3, 5, 6, 8, 11, 12, 13, 21, 24, 30, 42, 
43, 49, and 54, resulting in diffraction from 2.1 to 4 Å reso-
lution. Data processing and scaling was carried out with 
XDS/XSCALE [30]. The scaled data were then subjected 
to molecular replacement with the coordinates of 2pc4 
[26] followed by automatic refinement using the Phenix 
suite [31]. All coordinates were refined below an Rwork/Rfree 
of 28/32 prior to inspection of the electron density maps. 
Every dataset was visually inspected using Coot [32] and 
small molecule ligands were searched for either automati-
cally using the find unmodelled blob function or manually 
by inspecting the four TRAP binding sites of each aldolase 
subunit near residues R48 and R309. The ternary complex 
of PfAldolase–TRAP with compound 24 was refined to an 
Rwork/Rfree of 18.7/24.8 with one Ramachandran outlier as 
reported by Molprobity [33]. Compound 24 ligand occu-
pancy was automatically refined using Phenix refine to 
0.81–0.87, indicating a high occupancy of the compound 
in the four binding sites. A summary of the data reduc-
tion and refinement statistics are provided in Table 1. The 
structure factors and coordinates of the final model have 
been deposited with the PDB under accession code 4TR9.
Surface plasmon resonance assay
A CM5 chip was prepared and conjugated with Neutra-
vidin, allowing the subsequent capturing of biotinylated 
peptides, as described in [34]. All experiments were 
Table 1 Data collection and  refinement statistics for  PDB 
entry 4TR9
Statistics for the highest-resolution shell are shown in parentheses.
Beam line SSRL 12‑2, micro focus
Wavelength (Å) 0.9795
Resolution range (Å) 44.85–2.11 (2.19–2.11)
Space group P 21 21 21
Unit cell (Å, °) 69.89 139.56 142.10 90 90 90
Total reflections 281,841 (1,566)
Unique reflections 49,244 (642)
Multiplicity 5.7 (2.4)
Completeness (%) 61.09 (8.08)















Ramachandran favoured (%) 94






Page 5 of 18Nemetski et al. Malar J  (2015) 14:324 
carried out at 25 °C using a running buffer consisting of 
10 mM Hepes pH 7.5, 150 mM NaCl, 1 mM MgCl2, 0.2 % 
Tween 20, 1  % DMSO. Purified PfAldolase was passed 
over a reference flow cell as well as over a PfTRAP-, 
PvTRAP- and PfMTRAP-tail exposing surface. Binding 
of PfAldolase was measured in the presence of different 
concentrations ranging from 125 to 1,000  µM of com-
pound 24. All measurements were performed in tripli-
cates interspersed by blank injections. Data analysis was 
carried out with Scrubber (BioLogic Software) using 
double referencing method and correcting for DMSO 
absorption effects.
Hepatocyte viability assay
The VLS hits were screened for their affects on cultured 
HC-04 hepatocytes (ATCC, Manassas, VA, USA) as pre-
viously described [35–37]. To determine toxicity of com-
pounds 1, 3, 24, 42 and 43 on human hepatocytes, human 
hepatocyte cell line HC-04 capable of supporting P. falci-
parum development in vitro [38] was exposed to 1 mM 
of each compound for 96 h followed by Annexin V-APC 
and Propidium Iodide staining done according to manu-
facturer’s instructions (Apoptosis Detection Kit, eBiosci-
ence Inc, San Diego, CA, USA). Samples were analysed 
using flow cytometry (FACS-Scan, BD Biosciences) and 
the percentage of Annexin V negative/Propidium Iodide 
negative viable cells was calculated using FlowJo analysis 
software (Tree Star Inc, Ashland, OR, USA).
Sporozoite motility assay
Compounds were tested for their effect on P. berghei 
sporozoite motility using established protocols [39, 40] For 
the assays described here, sporozoites were pre-incubated 
with each compound at 500 μM for 10 min at 28 °C and 
the sporozoites remained in the presence of the compound 
(or DMSO) during the 1 h-long assay at 37 °C. The quan-
tity of motile parasites, and the numbers of their trails 
were then calculated to assess the compounds’ effects.
Sporozoite invasion assay
The sporozoite neutralization assay was carried out as 
previously described [41]. Briefly, P. berghei sporozoites 
were pre-incubated with 500 μM of the drugs or DMSO, 
and then allowed to infect human HepG2 cells (ATCC 
Collection). The HepG2 cells were collected after 40  h, 
and the infectivity of the parasites was quantified by real-
time PCR using primers specific for the P. berghei 18S 
rRNA [42].
Results
Identification of ligand‑accessible pockets through VLS
Small molecules with the potential to stabilize the inter-
action of the hybrid interface of TRAP with PfAldolase 
were identified by VLS on a previously described co-crys-
tal structure of P. falciparum aldolase in complex with a 
short cytoplasmic tail of TRAP [26] (Fig. 1b). A necessary 
feature for targeting a particular molecular surface with 
VLS is the presence of an optimally located, appropriately 
sized ‘druggable pocket’ (i.e., a ligand-accessible cavity or 
surface) against which to screen a chemical library [43]. 
Suitable pockets in the PfAldolase–TRAP target (PDB 
code 2pc4, 2.4 Å resolution, Rwork/Rfree = 20.1/25.0) [26] 
were located with the ICM PocketFinder [25] (Molsoft, 
LLC., La Jolla, CA, USA), setting pocket form and iden-
tity as key strategic parameters. For the present experi-
mental design, the pocket walls needed to be formed by 
the mixed surface of both TRAP and PfAldolase (Fig. 1b). 
As shown in Fig. 2a, b and Additional file 1, three pockets 
Fig. 2 Overview of the PfAldolase–TRAP druggable pockets. a Potential ligand-binding pockets in PfAldolase. Eight pockets were identified in 
the cocrystal structure of aldolase bound to TRAP (PDB ID: 2pc4 [26]). Aldolase is shown as a ribbon coloured in a smooth gradient from blue at 
its N-terminus to red at its C-terminus. TRAP is shown as a green ball-and-stick model. Only pockets 3, 6 and 8 are displayed because these three 
were targeted by the design with VLS since they are contacted by three non-conserved residues within aldolase—N51, E85, L117 (green balls-
and-sticks)—as well as by the TRAP peptide. b Plot of the surface area (Å2) vs volume (Å3) for the eight pockets. Pockets 1, 2 and 3 fall within the 
100–500 Å2/3 area/volume range, which is the usual area/volume for most FDA-approved drugs, following Lipinski’s rule of five [70].
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(coloured yellow, purple, and orange, respectively) met 
this criteria. These pockets juxtapose with the TRAP 
binding site, contacting the non-conserved PfAldo-
lase residues, N51, E85 and L117, as well as TRAP itself 
(balls-and-sticks in the Figure). While two of the pock-
ets (purple and orange in Fig.  2a, b) individually have 
smaller-than-desirable area-to-volume ratios for drug 
binding [43], compound fragments fitting them could still 
be useful for a fragment-based approach to the design of 
the sought-after drug. Additionally, their key locations 
within the target region justified including them in the 
target VLS area.
Target site modelling
The precise conformation of the target pocket may 
strongly influence the selection of compounds by the 
VLS algorithm, as the target site is not flexible during 
the docking procedure. Therefore, in addition to screen-
ing the co-crystal structure of P. falciparum aldolase 
bound to a hexapeptide derived from the C-terminus 
of P. berghei TRAP6 (PDB ID 2pc4, ‘2pc4 model’), addi-
tional screens were carried out against two additional 
models of the complex generated in silico: one in which 
the P. berghei TRAP sequence (EDNDWN) was modi-
fied to its P. falciparum counterpart (EENEWN, ‘falci-
parum model’), and one in which the final TRAP residue 
was modified to alanine (EENDWA), in order to simulate 
induced fit via the ‘gapped-pocket’ method (‘gapped-
pocket model’) [44]. The different VLS receptor models 
and the areas in which the docking was concentrated are 
shown in Additional files 2 and 3.
Virtual hit group selection through target site docking
315,102 small molecules, representing a sub-set of the 
ChemBridge® hit2lead database (San Diego, CA, USA), 
were docked to the three different conformations of the 
target site using the ICM-VLS algorithm (Molsoft LLC, 
La Jolla, CA, USA). Three independent virtual screens 
against each receptor model, specifically targeting the 
PfAldolase–TRAP interface and surrounding residues, 
yielded 182 unique hits. To further narrow this prese-
lection, these 182 compounds were re-docked to their 
respective receptors using the slower, more energetically 
accurate ICM-DOCK algorithm (Molsoft LLC, La Jolla, 
CA, USA). This step eliminated hits whose re-docked 
poses and/or energy scores differed significantly from the 
initial VLS results, as well as those with predicted lipo-
philicity (partition coefficients; cLogP) <−2 or >4. 60 of 
the 69 remaining compounds were then purchased from 
ChemBridge (San Diego, CA, USA) for in vitro and cell-
based assay testing. The individual small molecule struc-
tures as well as details of the VLS and docking results for 
these 60 compounds are listed in Additional file 4.
In vitro hit validation by enzymatic activity and thermal 
stability assays
In keeping with the novel hypothesis presented here, the 
initial 60 docking hits were subjected to biochemical and 
biophysical tests to identify those small molecules that 
would actually enhance the PfAldolase–TRAP interac-
tion and thereby occlude access of fructose 1,6-bispho-
sphate as a substrate to the active site of the enzyme 
(Fig.  1b). As mentioned above, TRAP binding has an 
inhibitory effect on aldolase’s glycolytic activity as previ-
ously demonstrated [26] (Fig. 1b).
To this end, the effects of the 60 pre-selected VLS hit 
compounds on PfAldolase’s enzyme activity were first 
investigated in the presence and absence of TRAP. TRAP 
is a competitive inhibitor of PfAldolase as the binding 
sites of the glycolytic substrate fructose 1,6-bisphos-
phate (F16BP) and TRAP partially overlap [26]. Follow-
ing the method of Döbeli et al. [22], PfAldolase enzyme 
activity was assayed by monitoring NADH consumption. 
The presence of the inhibitor TRAP expectedly caused a 
dose-dependent decrease in NADH consumption as pre-
viously published [26]. Hit compounds were considered 
potential stabilizers of the PfAldolase–TRAP interac-
tion if they promoted an additional decrease in NADH 
consumption/PfAldolase activity in the presence versus 
absence of TRAP. The change in the Vmax-rate compared 
to the attenuated PfAldolase–TRAP control distinguishes 
between inhibitory molecules with a negative ∆Vmax 
and TRAP-displacing molecules with a positive ∆Vmax 
(Fig. 3a). TRAP-displacing molecules would likely inter-
fere with human aldolase as the residues to which TRAP 
binds are identical between human and Plasmodium 
aldolase and are therefore undesired hits [26]. In order to 
identify sequence-specific differences in compound bind-
ing, all 60 VLS hits were assayed independently against 
PfAldolase with peptides derived from either P. berghei 
(DWA) or P. falciparum TRAP (DWN).
Furthermore, the thermal stability [27] of the PfAldo-
lase–TRAP complex was investigated with or without 
enzyme inhibition promoting hit compounds, in order to 
exclude effects resulting merely from structural destabili-
zation due to compound addition. The melting tempera-
ture (TM) of the PfAldolase–TRAP complex was assayed 
in the presence versus absence of hit compounds, where 
a strongly negative TM-shift would indicate a destabiliz-
ing, denaturing effect. However, compounds causing only 
marginally negative TM’s or positive TM’s shifts compared 
to the PfAldolase–TRAP control were considered as 
potentially viable hits for further analysis (Fig. 3b, c).
At 100 μM final concentration of the compounds, 13 
(compounds 3, 5, 14, 15, 18, 25, 26, 28, 33, 42, 43, 47, 
and 48) produced a positive shift of >2  °C in the melt-
ing point of a complex of recombinant P. falciparum 
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aldolase and the same P. berghei TRAP hexapeptide used 
to solve the TRAP–aldolase co-crystal structure, sug-
gesting a stabilizing effect (Fig. 3b, c). Interestingly, five 
compounds produced a negative TM shift of >2 °C com-
pared to the control (compounds 3, 5, 14, 15, 43) when 
no TRAP-peptide was present, some of which could 
then be stabilized when TRAP was added (Fig. 3c, third 
panel).
Preliminary ligand based SAR analysis after primary screen
Many of the VLS hits share similar chemical scaffolds 
(Fig. 4; Additional file 4). In particular, many of the com-
pounds that were active in the catalysis or thermal shift 
assays, including compounds 1, 9, 13, 16, 17, 19, and 21, 
as well as compounds 18, 24 and 42, which were also 
active in in  vitro motility and cell invasion assays (see 
below), contained N-(benzylideneamino)benzamide 
(Fig.  4b). The docking results and the crystallographic 
data for the active compounds suggest that several of 
these hits also make similar hydrogen-bonding and elec-
trostatic contacts with the PfAldolase–TRAP complex 
via functional groups extending off of the scaffold’s two 
benzene rings (Additional file 5).
In vitro parasite hit validation by gliding motility and liver 
cell invasion assays
Twelve of the biochemically-validated compounds were 
assayed for their effects on parasite motility and infec-
tivity. As shown in Fig.  5 and Additional file  6, two of 
the compounds, 24 and 42, had a pronounced effect on 
Fig. 3 PfAldolase catalytic activity and thermal stability in the presence of compounds. a Normalized bar graph representing the change in ∆Vmax 
relative to the control in the presence of each of the 60 ordered compounds. All assays were carried out in the presence of TRAP as used for the 
reference control. A negative ∆Vmax indicates further inhibition of glycolysis in the presence of the compound compared to PfAldolase with TRAP 
only. A positive ∆Vmax indicates displacement of TRAP by the compound resulting in an increased catalytic activity. Compounds inhibiting invasion 
in an in vitro culture assay are numbered in the plot (see Fig. 5). b Thermal stability assay derivative curves of four controls of PfAldolase with PfTRAP. 
The TM is indicted by the minima of the derivative at approximately 65 °C. c Average of a triplicate thermal stability assay in the presence of small 
molecules with and without PfTRAP peptide. The green bar represents the melting temperature of the control without compound. The change in 
thermal stability (∆TM) in the presence of PfTRAP per compound is depicted in the last graph. The dotted line represents the cutoff of a shift greater 
than 1.5 °C.
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gliding motility when assayed at 500 μM against isolated 
P. berghei sporozoites.
These same compounds, as well as compound 18, 
impaired the ability of parasites to invade hepatocytes 
when tested at 500  μM in a sporozoite neutralization 
assay [41, 42]. As shown in Fig.  5 and Additional file  6, 
compounds 18, 24 and 42 produced 58, 95 and 34 % inhi-
bition of hepatocyte invasion, respectively as assayed by 
RT-PCR of P. berghei 18S ribosomal copy number. Inter-
estingly, eight of the compounds (1, 3, 5, 19, 21, 29, 32, 
and 36) produced a trend towards increased infectivity of 
sporozoites.
Initial cytotoxicity study on human hepatocytes via flow 
cytometry
Those compounds showing activity in vitro and in vitro 
parasite assays (Fig. 5; Additional file 6) were also assayed 
for their effects on the viability of human HC-04 liver 
cells. As shown in Fig.  6, preliminary studies using 
1  mM of five selected compounds in 1  % final DMSO 
concentration do not show the induction of apoptotic 
markers as assayed by annexin V and phosphoinositol 
(PI)-staining after 96  h incubation. Taking these results 
together, they suggest that these compounds are indeed 
parasite-specific.
Ternary co‑crystal structure confirms mode of action 
of compound 24
Well-diffracting crystals of the ternary complex PfAldo-
lase–TRAP were obtained in the presence of various 
compounds. However in only one case, that of compound 
24, clear electron density was observed for both TRAP 
and the compound in all four sub-units of the aldolase 
tetramer (Fig.  7a; Additional files 7, 8, 9, 10). Notably, 
in the previously published aldolase–TRAP co-crystal 
structure (PDB ID: 2pc4) [26], TRAP could only be seen 
in one out of four aldolase sub-units, further highlighting 
the stabilizing effect of this compound on the complex. 
It is worth noting that the superposition comparison 
between 2pc4 [26] and the aldolase–TRAP–compound 
24 ternary complex reveals significant shifts of the 
TRAP-binding position upon addition of compound 24. 
The W604 ring system varies only slightly in its position 
by 0.8 Å (Fig. 7b), whereas the D603 Ca-position shifts by 
3.6  Å and the N605 Ca-position by 4.7  Å (Fig.  7c). The 
largest observed distance between the two crystal struc-
tures is the side chain of residue D603 with 8  Å. Over-
all, the TRAP-tails are pushed further into the pocket of 
aldolase upon addition of the small molecule stabilizer, 
compound 24, thereby occluding the F16P substrate-
binding site (Additional file  11). The dihydroxybenzyl-
ring of compound 24 stays within the experimental error 
of the X-ray crystal structure in the same position in all 
four sub-units, contacting residue N606 of TRAP and 
N39, E40, T44 of aldolase through hydrophobic interac-
tions. The dichlorobenzyl-ring system adopts two major 
conformations, indicating flexibility of the compound 
when bound to the PfAldolase–TRAP interface (Figs. 7c, 
8, Additional files 3, 4, 5, 6, 7, 8, 9, 10). The contacting 
residues on aldolase mainly provide hydrophobic interac-
tions mediated through residues L117, R158 and L198 for 
binding mode 1 and T44, K47 and R48 in the alternative 
conformation, while also contacting D604 of the TRAP-
tail. A future derivative of compound 24 with a double 
ring system at this position may confer higher binding 
Fig. 4 Identified scaffold and chemical formulas. a Chemical formu-
las of compounds 18, 24 and 42 showing a phenotypic effect on par-
asite gliding and parasite invasion of liver cells. b Frequently observed 
common scaffold of our VLS hits was a N-(benzylideneamino)
benzamide ring system.
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affinities to the PfAldolase–TRAP complex by decreasing 
the rotational freedom of the compound in the binding 
site. 
When comparing the predicted binding pose of com-
pound 24 from VLS with the actual experimentally 
observed in the crystal structure, one can observe a 
reasonable good agreement of the proximity of the ligand 
(Additional file  12). The motion of the TRAP-peptide 
deeper into the PfAldolase active site introduces signifi-
cant changes that currently cannot be computationally 
predicted a priori. When re-docking compound 24 to the 
actual observed ternary co-crystal structure (4TR9), the 
Fig. 6 Evaluation of compound cytotoxicity on human hepatocytes. Human hepatocytes (HC-04 cells) were treated with 1 mM of the compounds, 
and then analysed for the expression of apoptotic markers [via Annexin V-APC (FL4) and Propidium Iodide (FL2) staining] by flow cytometry. 
Representative examples of a sub-set of the compounds tested. Recovered cells were then analysed for the expression of both apoptotic markers 
Annexin-V and PI. At this concentration, none of the compounds induced heightened expression of either apoptotic markers [via Annexin V-APC 
(FL4) and Propidium Iodide (FL2) staining] by flow cytometry. Note that for compound 24, the fluorescence peaks for Annexin-APC are shifted 
slightly to the right, indicating that at higher concentrations, some cytotoxicity would likely be observed. However, the compound dosage used 
here—1 mM—is already much higher than would typically be observed under physiological conditions.
(See figure on previous page.)
Fig. 5 Gliding motility and hepatocyte invasion assay in the presence of compounds. a Compounds 24 and 42 impair the ability of P. berghei sporo-
zoites to glide on glass coverslips. The total height of bars represent the percentage of sporozoites that were motile (produced one or more trails on 
a glass slide) during the assay period. Untreated sporozoites produce >10 trails under the assay conditions. As shown here, sporozoites treated with 
compounds 24 or 42 were less motile overall and produced fewer trails than the DMSO controls. In this experiment, treatment with DMSO, com-
pound 24, or compound 42 produced 85, 33, and 38 % motile sporozoites, respectively. Fluorescent microscopy images of a representative sporozo-
ite (green crescent) and its gliding path (green spirals) for three assay treatments: DMSO control (left), compound 24 (centre), and compound 42 (right). 
Sporozoite trails were visualized using a biotinylated antibody to CSP. While some sporozoites treated with compounds 24 or 42 did produce >10 
trails, most of them produced no or few trails as shown here. b HepG2 liver invasion assay in the presence of small molecules. Compounds 18, 24, 
and 42 produced 58.9, 95.6 and 34 % inhibition of invasion, respectively. Note the logarithmic scale. c Real time PCR of the host cell GAPDH mRNA 
was used as a control for equal amounts present in each assay.
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predicted pose results in a better overlap, with a prefer-
ence for the binding mode 2 where the dichloroben-
zyl-ring system is in contact with T44, K47 and R48 
(Additional file 12).
Compound 24 does not cross‑react with rabbit aldolase
To validate that this initial hit compound represents a 
viable drug candidate, enzymatic assays were performed 
with rabbit aldolase, which is 99 % sequence identical to 
human aldolase (Additional file  1). Only four residues 
out of 364 vary between these two species, while Plas-
modium shares only 56  % sequence identity (203/364 
identical residues) with rabbit aldolase or human aldo-
lase (Additional file 1). A dilution series of compound 24, 
ranging from 250 to 0 µM was tested with rabbit aldolase, 
PfAldolase, and PfAldolase in the presence of the TRAP-
peptide. While compound 24 did not induce a significant 
change in activity in the rabbit aldolase or PfAldolase 
alone, a dramatic change in activity was observed upon 
addition of both the TRAP-peptide and compound 24 to 
PfAldolase, further supporting the initial hypothesis of 
compound 24 acting as a stabilizing agent of the PfAldo-
lase–TRAP protein–protein interaction (Fig.  9). Com-
pound 24 inhibits PfAldolase catalytic activity only in the 
presence of TRAP.
Surface plasmon resonance (SPR) studies indicate 
decreased dissociation rates of the PfAldolase–TRAP 
complex in the presence of compound 24
The authors recently devised a method [34] by which 
screening and characterization of small molecules that 
enhance the binding of PfAldolase and TRAP can be 
performed. The binding of either PfAldolase to immobi-
lized TRAP peptides or binding of TRAP to immobilized 
Fig. 7 Ternary co-crystal structure of PfAldolase with TRAP and compound 24. a Panel showing all four sub-units of PfAldolase bound with TRAP 
(blue 2Fo-Fc map at 1.5 s level) and compound 24 (green difference density map at 3 s level). b Superposition of compound 24 relative to the 
TRAP-tails, TRAP is represented as transparent surface. While all four TRAP-tails are in an almost identical position, compound 24 adopts two major 
conformations. c Structural comparison of the PfAldolase–TRAP complex 2PC4 (grey [26]) with PfAldolase–TRAP–Cmp 24 complex 4TR9 (green and 
magenta). Binding of compound 24 to the PfAldolase–TRAP interface results in a dramatic inward movement of TRAP compared to our previous 
structure of PfAldolase with TRAP alone (2PC4, [26]).
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PfAldolase on a SPR chip has been previously demon-
strated [34, 45]. In this study PfAldolase was passed over 
a chip with immobilized TRAP-peptides to measure the 
binding and dissociation in the presence of compound 24 
(Fig. 10). The association constant (Ka) decreases and the 
dissociation rate (Kd) increases in the presence of com-
pound 24, thereby indicating a stabilizing effect on the 
PfAldolase–TRAP complex under physiological buffer 
conditions. A dose-dependent delay in dissociation of 
~5  s can be observed with concentrations >500  µM as 
indicated by dotted lines in Fig.  10. At the highest con-
centration tested of 1,000 µM the dissociation is delayed 
by ~10 s, providing a biophysical real time observation of 
the binding promoting capabilities of compound 24. No 
delayed dissociation effect is observed with lower con-
centrations of the compound than those depicted.
Discussion
Here, the challenge to pharmacologic targeting of a site 
strongly conserved in amino acid sequence between 
human and parasite in the key aldolase protein of the 
Plasmodium glideosome was overcome by successfully 
designing a screen for compounds that specifically stabi-
lize a key protein–protein interface between PfAldolase 
and TRAP in the malaria parasite. The proposed bind-
ing mode of the stabilizing compound was confirmed in 
the ternary Aldolase–TRAP–C24 co-crystal structure 
(Figs. 7, 8, Additional files 7, 8, 9). Since the compounds 
Fig. 8 Detailed interaction representation of compound 24 with the PfAldolase–TRAP interface. The electrostatic surface of the mixed interface is 
shown and compound 24 is kept in a green-stick representation. Figure generated in Vida [71] and rendered with Povray [72].
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also inhibited parasite motility and invasion (Figs. 5, 11, 
Additional file  6), they suggest that this interface in the 
glideosome is a relevant target for anti-malarial drug 
design. Furthermore, an additional effect of stabilizing 
the PfAldolase–TRAP interface may result in the occlu-
sion of the actin-binding site to PfAldolase and thereby 
preventing actin binding, which is needed for a produc-
tive invasion event, hence potentiating the effect of the 
stabilizing ligand. Importantly, by stabilizing TRAP 
bound to aldolase, compound 24 also potentiates aldo-
lase inhibition by the TRAP protein (Figs. 7, 8, Additional 
file 9), enhancing their appeal as drug candidates. A ter-
nary complex of aldolase–TRAP and compound 24 can 
be rendered catalytically inactive with appropriate com-
pound concentrations, thereby having a limiting effect 
on energy production of the parasite through glycolysis. 
Further structural and biochemical studies should help 
delineate the extent to which inhibition of glycolysis con-
tributes to the compounds’ anti-infective effect versus 
direct interference with the glideosome’s physical mecha-
nism of movement generation.
Of note, recent studies have called into question the 
conservation of the gliding machinery across Apicom-
plexa, and in particular the role played by aldolase in 
infectivity. Shen et al. showed that one aldolase isozyme 
(TgALD1) can be knocked out, and the altered parasites 
retain infectivity, although to a much lower degree [46]. 
In contrast, a recent study utilizing biolayer interferom-
etry, as well as co-sedimentation studies, confirmed that 
aldolase and actin are required for Plasmodium for cell 
invasion of host cells [47], although this individual study 
is not considered definitive. The reader is referred to a 
recent comprehensive review discussing the similarities 
and differences of the glideosomes in Toxoplasma and 
Plasmodium [48] In addition to representing potential 
new leads in anti-malarial drug design, the compounds 
and methods described here represent an important 
new strategy for the field by providing new pharmacol-
ogy (non-genetic) tools that may help clarify the Toxo-
plasma genetic studies. The most selective compounds 
could be valuable non-genetic tools for further investi-
gating glideosome function in Plasmodium. At the con-
centrations tested, compound 24 did not inhibit rabbit 
aldolase, which was utilized as a surrogate for human 
aldolase with 99.3 % sequence identity (Fig. 9; Additional 
file  1). In addition, our studies suggest that the genetic 
findings in Toxoplasma may not apply to other biomedi-
cally important members of the Apicomplexan phylum 
[26].
Fig. 9 Inhibition assay of Rabbit and Plasmodium aldolase with 
compound 24. Rabbit aldolase was utilized as a surrogate for human 
aldolase due to the sequence identity. Different concentrations 
of compound 24 were tested in the presence and absence of the 
TRAP-peptide. No apparent inhibition is observed in either rabbit 
or Plasmodium aldolase alone, while a strong inhibition is observed 
when TRAP is present. Assays were performed in triplicate under 
standard conditions.
Fig. 10 Delayed dissociation of TRAP bound to PfAldolase meas-
ured via SPR. Dose-dependent dissociation delay of PfTRAP-tail from 
PfAldolase immobilized on an SPR chip. A fixed amount of PfTRAP-tail 
fused via a linker to Maltose binding protein was measured in the 
presence of increasing concentrations of compound 24 using SPR. 
Indicated with dashed lines is the dissociation delay observed at 
concentrations greater than 500 µM of compound 24.
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Although proof-of-principle was achieved, the com-
pounds exhibit relatively low potencies in functional 
assays, which is a limitation for their development into 
drug leads. Nevertheless, the potency of the hits them-
selves may be less important than validation of the target 
drug-binding pocket by structure-based screening: the 
pharmacophore space that is now mapped out by the hits 
and their bioactivities, in conjunction with the known 
interactions within the X-ray crystal structure, can serve 
as a blueprint for rational optimization of the hits in mul-
tiple directions (better potency, better bioavailability, 
etc.), using resources such as medicinal chemistry and 
fragment-based tethering. Notably, the GSK TCAMS 
[49] Novartis-GNF Malaria Box, and St Jude Children’s 
Research Hospital [50] datasets of hits from whole-cell 
screenings against P. falciparum blood stages include sev-
eral compounds containing the N-(benzylideneamino)
benzamide scaffold between them (Additional file  13). 
This scaffold is shared by some of the hits identified here 
(Fig.  4a), and medicinal chemistry derivatization of this 
scaffold may yield additional compounds with greater 
potency against the parasite or other favourable drug 
properties. It should also be noted that the average con-
centration of FDA approved drugs used to treat malarial 
disease in humans is close to 500 µM. For example, when 
injected intravenously the usual formulation of Chloro-
quine employed is 200 mg/ml, resulting in approximately 
100  µM final concentration in the blood. Malarone, a 
combination therapy of atovaquone and proguanil is 
given as an oral dose at 750 mg/5 ml (~410 mM), corre-
sponding to approximately 30 µM final concentration for 
a 60-kg person, assuming equal biodistribution through-
out the body [51].
One intuitive, theoretical concern related to this study is 
that compounds targeted to the PfAldolase–TRAP inter-
face may actually destabilize the complex or that stabilizing 
the target interface might enhance motility and infectiv-
ity. Indeed, several compounds showed destabilization on 
Fig. 11 Triaging of VLS hits via primary screen and validation through secondary parasite assays. a Venn diagrams of our primary screen using 
VLS, enzyme activity assay and thermal shift data. 36 compounds showed activity in more than one assay. b Venn diagram of those compounds 
overlapping in at least two assays in our primary screens, gliding motility assay and liver invasion assay. Compound 24 emerges from five different 
assays and was the only one successfully visualized through our co-crystallization efforts. c Flowchart depicting the sequence of steps in the lead 
identification and verification process described here. While initially 315,105 chemical structures were screened using VLS, after each step fewer 
viable drug candidates remained. At the end of this sequence of computational and biochemical experiments, compound 24 emerged as the most 
promising lead.
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thermal shift. Notably, only the last three residues of TRAP 
(604–605) were visible in the crystal structure and recep-
tor models which were screened against here. It is possible 
that these compounds interact in an inhibitory way with 
upstream TRAP residues that could not be accounted for 
in this screen. If so, these compounds may be the basis for 
a new approach to inhibit the glideosome as they should 
be even more specific. Destabilizing compounds, although 
not desired by the present design, may actually be useful 
from a drug development point of view once their exact 
mechanism of action is known. Additionally, eight com-
pounds showed insignificant trends towards increases in 
invasion despite no change or decreases in motility, possi-
bly indicating that some of the compounds may have addi-
tional off-target effects or change the PfAldolase–TRAP 
interaction in a way that increases invasion but not motil-
ity. As the precise chemistry and mechanism of the glideo-
some is still obscure, these possibilities cannot be ruled 
out. Compounds having this effect may nevertheless be 
useful non-genetic tools for studying precise glideosome 
sub-mechanisms.
Most drugs in use today inhibit biological interactions. 
However, the scientific literature contains several exam-
ples of biologically active small molecules that function 
by stabilizing protein–protein interactions in a bipartite 
manner, including fungal toxins [52–54], chemothera-
peutic agents [55–59], antibiotics [60, 61], and immu-
nosuppressants [62]. These examples indicate, and the 
results here ultimately suggest, that it could be possible 
to develop clinically useful compounds that enhance PPI. 
For a small molecule to inhibit a PPI, it must bind to its 
receptor with a higher affinity than, and at least similar 
specificity to, the protein’s native ligand. A vast collec-
tion of failed drug candidates demonstrates how diffi-
cult it is to compete with eons of evolutionary pressure 
that produced the biomolecular interaction in the first 
place [63]. Stabilizing that interaction, however, does not 
require competing with nature, as a nearby region is tar-
geted by the small molecule. Rather, this approach tries 
to nudge the interaction’s equilibrium in the direction 
that is thermodynamically favoured to begin with. Thus a 
candidate enhancer does not need to bind either member 
of a protein complex with particularly high affinity—it is 
the aggregate of affinities of the proteins for each other 
and for the drug that matter [54]. As demonstrated by the 
compounds discovered here, adding just one or two con-
tact points to a protein complex can make a very big dif-
ference in its stability.
The enhancer approach may work especially well for 
situations in which the conformational dynamics of a 
protein complex are key to its function. In this case, the 
ability of the glideosome to provide the motive force is 
dependent on the highly coordinated interactions of its 
members. Aldolase must tightly bind both actin and 
TRAP to allow motion to begin, but it must also rapidly 
release the TRAP tail after its cleavage to allow motion to 
continue. While it is unclear if the same pool of aldolase 
participates in both motility and glycolysis, the enzymatic 
binding and cleavage of F16P is crucial for providing the 
ATP molecules necessary for the actin-myosin power 
stroke [29, 64]. The various conformations of aldolase, 
TRAP, actin, and MyosinA must therefore exist in the 
ideal equilibriums to promote the proper bind-and-
release sequences for each of the glideosome interac-
tions. Shifting these equilibrium in either direction by 
inhibiting or enhancing any of the interactions involved 
should affect the motor. The computer-aided, structure-
based approach to drug discovery presented here allowed 
the specific targeting of structural differences between 
multiple conformations of aldolase in order to shift the 
apo-aldolase/aldolase-F16P/aldolase–TRAP equilib-
rium towards the aldolase–TRAP complex in a parasite-
selective fashion. Nature abounds with similar vulnerable 
systems of exquisitely regulated biological motors and 
complexes, many of which might be targeted by this 
structure-based enhancer method.
Future modelling and crystallographic studies should 
help define additional receptor pockets and conforma-
tions that can be exploited to design compounds that 
target different aspects of the glideosome, including the 
glideosome homologs present in different stages of the 
Plasmodium life-cycle, as well as glideosome components 
conserved in other apicomplexan pathogens, such as 
Toxoplasma gondii and Cryptosporidium spp. For exam-
ple, given sufficient structural information, the interac-
tions between MTIP and Myosin A in Plasmodium could 
also be targeted in a similar fashion to the TRAP–aldo-
lase complex by either stabilizing the close conformation 
or preventing opening of the EF-hands of MTIP. Several 
structures of PfMTIP and PkMTIP in complex with Myo-
sin A [65–67] and stapled peptides [68, 69] have been 
described to date. Analysis of their structural flexibility 
may provide crucial insights towards targetable interfaces 
and pockets.
While stabilizing the PfAldolase–TRAP interaction 
may seem like an unusual approach for rational drug 
design, by targeting this joint surface, the avenue it opens 
to promoting parasite specificity—TRAP is not present 
in humans—may prevent the emergence of resistance. 
Additionally, resistance mutations in aldolase’s active site 
would be highly unfavourable as they would likely inter-
fere with glycolytic energy generation. Starnes et al. [64] 
demonstrated in Toxoplasma that mutations near the 
active site of aldolase are not tolerated by the parasite, 
which is in agreement with the decreased likelihood of 
resistance mutations emerging.
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The strategy of targeting a hybrid surface composed 
of a conserved target and a non-conserved target for the 
purposes of combating resistance may be broadly appli-
cable to structure-based drug design. This may be espe-
cially useful for developing agents to fight eukaryotic 
pathogens, as many of their essential proteins have highly 
conserved human homologues, and are otherwise diffi-
cult to specifically target. It may also be possible to use 
this type of approach to design therapeutics for rapidly 
mutating viruses by selectively modulating host-path-
ogen interactions, i.e. preventing the dissociation of a 
viral surface protein with its host receptor may increase 
the virus’s vulnerability to other drugs or to the host’s 
own immune system. In this case, the druggable surface 
encompassing the viral protein would provide specificity, 
while the unlikelihood of mutations in the host protein 
may protect against the development of drug resistance. 
Similarly, one can envision targeting a complex of a nor-
mal housekeeping protein and a mutant oncoprotein to 
selectively kill cancer cells.
It is important to note that the compounds and chemi-
cal scaffolds identified here are not found among the 
anti-malarials currently in clinical use. The fact, that the 
identified compound emerged directly from a VLS effort 
and has not undergone any chemical optimization, while 
showing an on-target effect by various biophysical and 
parasitological assays bodes well for its future devel-
opment from a probe to a lead compound. This effort, 
therefore, represents a successful ‘scaffold hop’ in anti-
malarial drug discovery. If ultimately successful, these 
drugs and their derivatives would constitute a novel class 
or classes of anti-malarial agents, as well as the first drugs 
to target the aldolase–TRAP interaction.
At present, a more potent, safe drug with an identical 
mechanism of action to compound 24 could be useful 
for malaria prophylaxis, but its activity against merozo-
ites, the extracellular form of the erythrocytic stage para-
sites was negative, likely due to the additional C-terminal 
extension of the merozoite TRAP homologue MTRAP 
occluding binding of compound 24. Nevertheless, if the 
compounds identified here do not cross-react with mero-
zoites, a similar screen to that described in this study, tar-
geting MTRAP, the merozoite homologue of TRAP, could 
yield a similar, specific drug active in the blood stages. 
Based on the sequence identity of the terminal residues of 
TRAP with CTRP, the circumsporozoite TRAP-like pro-
tein (PlasmoDB code PF3D7_0315200) expressed dur-
ing the mosquito stage, it is anticipated that compound 
24 may function as a stabilizer of the PfAldolase–CTRP 
interface and be able to block mosquito midgut invasion 
of the parasite. Such a compound could perhaps be used 
as a spray to treat bednets or to treat hatching areas and 
prevent spread of mosquitoes carrying the parasite.
Conclusion
In summary, the results presented here validate the aldo-
lase–TRAP interaction within the Plasmodium glideosome 
as a drug discovery target, by proving both that it can be 
pharmacologically targeted and that doing so does affect 
the parasite’s motility and invasion capabilities. It remains 
to be determined, if a similar approach can succeed in Tox-
oplasma and other Apicomplexa, but using the chemical 
probes discovered here may contribute to the understand-
ing of the role of aldolase in Toxoplasma gliding motility.
This work also provides proof-of-concept that the 
structure-based, selective, enhancement of PPI is a viable, 
efficient and effective method of novel drug hit discovery, 
opening new avenues to drug discovery for challenging 
targets, such as the glideosome.
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